One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre

One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre

Abstract Background Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG). However, 1 year of PCV is associated with significant toxicities. In the pivotal RTOG 9802 randomised control trial, approximately hal...

Full description

Bibliographic Details
Main Authors: Rachel J. Keogh, Razia Aslam, Maeve A. Hennessy, Zac Coyne, Bryan T. Hennessy, Oscar S. Breathnach, Liam Grogan, Patrick G. Morris
Format: Article
Language:English
Published: BMC 2021-02-01
Series:BMC Cancer
Subjects:
Procarbazine
Lomustine
Vincristine
Chemotherapy
Glioma
Online Access:https://doi.org/10.1186/s12885-021-07809-5

Internet

https://doi.org/10.1186/s12885-021-07809-5

Similar Items